{
    "clinical_study": {
        "@rank": "21631", 
        "arm_group": [
            {
                "arm_group_label": "20 mg Fluoxetine", 
                "arm_group_type": "Experimental", 
                "description": "Capsules administered orally, once daily, for approximately 2 months"
            }, 
            {
                "arm_group_label": "40 mg Fluoxetine", 
                "arm_group_type": "Experimental", 
                "description": "Capsules administered orally, once daily, for approximately 2 months"
            }, 
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Capsules administered orally, once daily, for approximately 2 months"
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to evaluate the short-term efficacy and safety of Fluoxetine in\n      Japanese adult participants with MDD."
        }, 
        "brief_title": "A Study of Fluoxetine in Major Depressive Disorder (MDD) Short-Term Dosing", 
        "completion_date": {
            "#text": "July 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Major Depressive Disorder", 
        "condition_browse": {
            "mesh_term": [
                "Depressive Disorder", 
                "Depression", 
                "Depressive Disorder, Major"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Outpatient Japanese participants diagnosed with MDD\n\n          -  Diagnosis of moderate or greater severity of MDD\n\n          -  Agree to abstain from sexual activity or to use a reliable method of birth control\n\n          -  Judged to be reliable (agree to keep appointments for clinic visits and to undergo\n             all tests and examinations required by the protocol)\n\n        Exclusion Criteria:\n\n          -  Have previously been exposed to fluoxetine (LY110140) for any indication in the past\n\n          -  Significant suicidal risk\n\n          -  Have a current or previous diagnosis of bipolar disorder, psychotic depression,\n             schizophrenia or other psychotic disorder, anorexia, bulimia, obsessive compulsive\n             disorder, or post-traumatic stress disorder\n\n          -  Have a history of substance abuse or dependence within the past 6 months, excluding\n             caffeine and nicotine\n\n          -  Have initiated, stopped, or changed the type or intensity of psychotherapy  within 6\n             weeks\n\n          -  Have a history of electroconvulsive therapy (ECT), transcranial magnetic stimulation\n             (TMS), or vagus nerve stimulation (VNS) within 1 year\n\n          -  Have had treatment with a Monoamine oxidase inhibitor (MAOI) within 14 days\n\n          -  Need to use thioridazine or pimozide during the study\n\n          -  Have previously enrolled, completed, or withdrawn from this study\n\n          -  Have a positive urine drug screen for drugs with abuse potential\n\n          -  Female participants who are either pregnant, nursing, or have recently given birth,\n             or male participants who are planning for their partners to be or become pregnant\n\n          -  Have a history of seizure disorder\n\n          -  Have frequent or severe allergic reactions to multiple medications\n\n          -  Have a serious or unstable medical illness or condition, or psychological condition\n\n          -  Participants deemed ineligible by the investigator or sub-investigator for other\n             reasons"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "20 Years"
        }, 
        "enrollment": {
            "#text": "522", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "March 7, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01808612", 
            "org_study_id": "14595", 
            "secondary_id": "B1Y-JE-HCLV"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "20 mg Fluoxetine", 
                    "40 mg Fluoxetine"
                ], 
                "description": "Administered orally", 
                "intervention_name": "Fluoxetine", 
                "intervention_type": "Drug", 
                "other_name": [
                    "LY110140", 
                    "Fluoxetine Hydrochloride", 
                    "Prozac", 
                    "Sarafem"
                ]
            }, 
            {
                "arm_group_label": "Placebo", 
                "description": "Administered orally to maintain blind", 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Fluoxetine"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "lastchanged_date": "May 21, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Aichi", 
                        "country": "Japan", 
                        "zip": "471-8513"
                    }, 
                    "name": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician."
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Chiba", 
                        "country": "Japan", 
                        "zip": "270-0014"
                    }, 
                    "name": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician."
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Fukuoka", 
                        "country": "Japan", 
                        "zip": "800-0226"
                    }, 
                    "name": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician."
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Fukushima", 
                        "country": "Japan", 
                        "zip": "961-0021"
                    }, 
                    "name": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician."
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Hiroshima", 
                        "country": "Japan", 
                        "zip": "737-0143"
                    }, 
                    "name": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician."
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Hokkaido", 
                        "country": "Japan", 
                        "zip": "065-0012"
                    }, 
                    "name": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician."
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Hyogo", 
                        "country": "Japan", 
                        "zip": "651-0097"
                    }, 
                    "name": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician."
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Kanagawa", 
                        "country": "Japan", 
                        "zip": "238-0042"
                    }, 
                    "name": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician."
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Kyoto", 
                        "country": "Japan", 
                        "zip": "616-8421"
                    }, 
                    "name": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician."
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Nagano", 
                        "country": "Japan", 
                        "zip": "390-0303"
                    }, 
                    "name": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician."
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Okayama", 
                        "country": "Japan", 
                        "zip": "700-0907"
                    }, 
                    "name": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician."
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Osaka", 
                        "country": "Japan", 
                        "zip": "586-0012"
                    }, 
                    "name": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician."
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Saitama", 
                        "country": "Japan", 
                        "zip": "339-0057"
                    }, 
                    "name": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician."
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Shiga", 
                        "country": "Japan", 
                        "zip": "525-0037"
                    }, 
                    "name": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician."
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Tochigi", 
                        "country": "Japan", 
                        "zip": "321-0953"
                    }, 
                    "name": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician."
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Tokyo", 
                        "country": "Japan", 
                        "zip": "170-0002"
                    }, 
                    "name": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician."
                }
            }
        ], 
        "location_countries": {
            "country": "Japan"
        }, 
        "number_of_arms": "3", 
        "official_title": "A Phase 3, Randomized, Placebo-Controlled, Double-Blind, Parallel-Design Study to Evaluate the Short-Term, Fixed Dose Efficacy and Safety of LY110140 Once Daily Dosing in Japanese Patients With Major Depressive Disorder", 
        "overall_official": {
            "affiliation": "Eli Lilly and Company", 
            "last_name": "Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)", 
            "role": "Study Director"
        }, 
        "overall_status": "Active, not recruiting", 
        "oversight_info": {
            "authority": [
                "Japan: Pharmaceuticals and Medical Devices Agency", 
                "Japan: Ministry of Health, Labor and Welfare", 
                "Japan: Institutional Review Board"
            ], 
            "has_dmc": "No"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "July 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Mean Change from Baseline to Approximately Two Months on the 21-Item Hamilton Depression Rating Scale (HAMD21) Total Score", 
            "safety_issue": "No", 
            "time_frame": "Baseline, Approximately Two Months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01808612"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Mean Change from Baseline to Approximately Two Months on the HAMD21 Subscale Scores", 
                "safety_issue": "No", 
                "time_frame": "Baseline, Approximately Two Months"
            }, 
            {
                "measure": "Percentage of Participants Achieving a Response at Approximately Two Months", 
                "safety_issue": "No", 
                "time_frame": "Approximately Two Months"
            }, 
            {
                "measure": "Percentage of Participants Achieving a Remission at Approximately Two Months", 
                "safety_issue": "No", 
                "time_frame": "Approximately Two Months"
            }, 
            {
                "measure": "Mean Change from Baseline to Approximately Two Months on the Clinical Global Impression of Severity (CGI-S) Scale", 
                "safety_issue": "No", 
                "time_frame": "Baseline, Approximately Two Months"
            }, 
            {
                "measure": "Change from Baseline to Approximately Two Months in Sheehan Disability Scale (SDS) Total Score and Subscale Scores", 
                "safety_issue": "No", 
                "time_frame": "Baseline, Approximately Two Months"
            }, 
            {
                "measure": "Number of Participants with Suicidal Behaviors and Ideations Collected by Columbia - Suicide Severity Rating Scale (C-SSRS)", 
                "safety_issue": "Yes", 
                "time_frame": "Baseline to Approximately Two Months"
            }
        ], 
        "source": "Eli Lilly and Company", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Eli Lilly and Company", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "March 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}